Upgrade: Analysts Just Made A Sizeable Increase To Their Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG:2252) Forecasts
Celebrations may be in order for Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG:2252) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals. The market seems to be pricing in some improvement in the business too, with the stock up 7.7% over the past week, closing at HK$28.50. Could this big upgrade push the stock even higher?
After the upgrade, the six analysts covering Shanghai MicroPort MedBot (Group) are now predicting revenues of CN¥1.1b in 2026. If met, this would reflect a sizeable 107% improvement in sales compared to the last 12 months. The losses are expected to disappear over the next year or so, with forecasts for a profit of CN¥0.094 per share this year. Prior to this update, the analysts had been forecasting revenues of CN¥978m and earnings per share (EPS) of CN¥0.023 in 2026. So we can see there's been a pretty clear increase in analyst sentiment in recent times, with both revenues and earnings per share receiving a decent lift in the latest estimates.
View our latest analysis for Shanghai MicroPort MedBot (Group)
With these upgrades, we're not surprised to see that the analysts have lifted their price target 8.3% to CN¥30.99 per share. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Shanghai MicroPort MedBot (Group), with the most bullish analyst valuing it at CN¥36.75 and the most bearish at CN¥21.06 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Shanghai MicroPort MedBot (Group)'s rate of growth is expected to accelerate meaningfully, with the forecast 107% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 72% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 23% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Shanghai MicroPort MedBot (Group) to grow faster than the wider industry.
The Bottom Line
The biggest takeaway for us from these new estimates is that analysts upgraded their earnings per share estimates, with improved earnings power expected for this year. They also upgraded their revenue estimates for this year, and sales are expected to grow faster than the wider market. With a serious upgrade to expectations and a rising price target, it might be time to take another look at Shanghai MicroPort MedBot (Group).
Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Shanghai MicroPort MedBot (Group) analysts - going out to 2028, and you can see them free on our platform here.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.